Biomarkers Prostate

Imaging guidelines in newly diagnosed prostate cancer

Guideline

Categories

Imaging recommendation

EAU

Low-risk*

- No imaging

Intermediate-risk*; predominantly GI 4

- Multiparametric MRI for local staging 1!

- CT-abdomen/pelvis - Bone scan 2, 3, 4, 5!

High-risk*

- Multiparametric MRI for local staging - CT-abdomen/pelvis - Bone scan2, 3, 4, 5!

General / any risk

- No CT / TRUS for local staging - No Choline-PET for detection of LN-metastases - No final recommendation on Ga/F-PSMA PET - No final recommendation on WB-MRI

NCCN (Version : 2.2017)

If life expectancy >5y or asymptomatic AND: - T1 and PSA >20ng/ml - T2 and PSA >10ng/ml - Gleason 9 - T3 or T4

- Bone scan2, 3, 4, 5!

Symptomatic AND: - T3; T4; - T1-T2 and nomogram >10% risk of LN-metastases Cagiannos I., et al 7!

- CT/MRI

AUA/ASTRO SUO 2017

Very low and Low risk*

- No CT-abdomen/pelvis or Bone scan

Unfavourable Intermediate/ High-Risk*

- CT/MRI - Bone scan

IKNL
(Guideline prostate cancer, version 2.1)

- PSA >20ng/ml - cT3 - Gleason 8 - Symptomatic

- Bone scan or choline PET6!

General / any risk

- Multiparametric MRI for primary diagnosis (if available) 1!
- Multiparametric MRI for staging (only if relevant for therapy)

- No CT for staging
- No routine Choline-PET for primary Staging

* Low-risk: PSA < 10 ng/mL; GS < 7 (ISUP grade 1); cT1-2a
Intermediate-risk: PSA 10-20 ng/mL; GS 7 (ISUP grade 2/3) or cT2b
High-risk: PSA > 20 ng/mL; or GS > 7 (ISUP grade 4/5); or locally advanced

x Very Low Risk: PSA <10 ng/ml AND Grade Group 1 AND clinical stage T1-T2a AND <34% of biopsy cores positive AND no core with >50% involved, AND PSA density <0.15 ng/ml/cc
Low Risk: PSA <10 ng/ml AND Grade Group 1 AND clinical stage T1-T2a
Intermediate Risk: PSA 10-<20 ng/ml OR Grade Group 2-3 OR clinical stage T2b-c
Favorable: Grade Group 1 (with PSA 10-<20) OR Grade Group 2 (with PSA<10)
Unfavorable: Grade Group 2 (with either PSA 10-<20 or clinical stage T2b-c) OR Grade Group 3 (with PSA < 20)
High Risk: PSA >20 ng/ml OR Grade Group 4-5 OR clinical stage >T3 OR locally advanced

  1. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M; PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017 Feb 25;389(10071):815-822.
  2. Briganti A, Passoni N, Ferrari M, et al. When to Perform Bone Scan in Patients with Newly Diagnosed Prostate Cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification Tool. Eur Urol 2010; 57: 551–8.
  3. Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014; 43: 1503–13.
  4. Zacho HD, Manresa JAB, Aleksyniene R, et al. Three-minute SPECT/CT is sufficient for the assessment of bone metastasis as add-on to planar bone scintigraphy: prospective head-to-head comparison to 11-min SPECT/CT. EJNMMI Res 2017; 7: 1.
  5. Palmedo H, Marx C, Ebert A, et al. Whole-body SPECT/CT for bone scintigraphy: Diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging 2014; 41: 59–67.
  6. Beheshti M, Imamovic L, Broinger G, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254: 925–33.62.
  7. Cagiannos I, Karaciwicz P, Eastham JA, et al. A Preoperative Nomogram Identifying Decreased Risk of Positive Pelvic Lymph Nodes in Patients With Prostate Cancer. J Urol 2003; 170: 1798–803.

Imaging guidelines at biochemical recurrence of prostate cancer

Guideline

Categories

Imaging recommendation

EAU

After prostatectomy:

 

 

- PSA <1ng/ml

- No imaging

 

- PSA >1ng/ml

- Choline or PSMA-ligand PET8!

 

After radiotherapy:
(If fit enough for curative salvage)

- Multiparametric MRI - Choline-PET9, 10, 11! - Ga-PSMA PET no standard tool, yet should be considered if available12, 13, 14, 15, 16, 17, 18!

 

General / any risk: - Only if PSA >10ng/ml - PSAdt <6mnth - PSA velocity>0,5ng/ml/mo

- CT-abdomen/pelvis19, 20! - Bone scan19, 20! - No final recommendation on WB-MRI21, 22!

NCCN (Version : 2.2017)

After prostatectomy:

- Bone scan

 

After Radiotherapy
If candidate for local therapy
(T1-2, Nx or N0; Life expectancy >10y; PSA>10ng/ml)

- X-ray chest
- Bone scan
- Prostate MRI
Consider:
- CT/MRI-abdomen/pelvis
- C-11 Choline PET
23!

IKNL
(Guideline prostate cancer, version 2.1)

- PSA >5ng/ml - PSA >1ng/ml and PSAdt <3mo - Gleason 8

- Choline PET - Bone scan only if PSA >20ng/ml

 

General / any risk

- No CT for staging
Consider: - Multiparametric MRI for local recurrence

  1. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2017; 71: 618–29.
  2. Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM. The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2013; 64: 106–17.
  3. Evangelista L, Zattoni F, Guttilla A, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: A systematic review and meta-analysis. Clin. Nucl. Med. 2013; 38: 305–14.
  4. Treglia G, Ceriani L, Sadeghi R, Giovacchini G, Giovanella L. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: A meta-analysis. Clin Chem Lab Med 2014; 52: 725–33.
  5. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 486–95.
  6. Perera M, Papa N, Christidis D, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur. Urol. 2016; 70: 926–37.
  7. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. J Nucl Med 2015; 56: 1697–705.
  8. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015; 56: 668–74.
  9. Ceci F, Uprimny C, Nilica B, et al. 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 2015; 42: 1284–94.
  10. Montorsi F, Gandaglia G, Fossati N, et al. Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer. Eur Urol 2017; 72: 432–8.
  11. Maurer T, Weirich G, Schottelius M, et al. Prostate-specific Membrane Antigen-radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. Eur Urol 2015; 68: 530–4.
  12. Kane CJ, Amling CL, Johnstone PAS, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003; 61: 607–11.
  13. Lindenberg ML, Turkbey B, Mena E, Choyke PL. Imaging locally advanced, recurrent, and metastatic prostate cancer: A review. JAMA Oncol. 2017; 3: 1415–22.
  14. Eschmann SM, Pfannenberg AC, Rieger A, et al. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. NuklearMedizin. 2007; 46: 161–8.
  15. Zacho HD, Nielsen JB, Afshar-Oromieh A, Haberkorn U, deSouza N, De Paepe K, Dettmann K, Langkilde NC, Haarmark C, Fisker RV, Arp DT, Carl J, Jensen JB, Petersen LJ. Prospective comparison of (68)Ga-PSMA PET/CT, (18)F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018; 45:1884-1897. 
  16. Evangelista L, Zattoni F, Guttilla A, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: A systematic review and meta-analysis. Clin. Nucl. Med. 2013; 38: 305–14.

Imaging guidelines at the castrate resistant stage of prostate cancer

Guideline

CRPC (APC)

Imaging recommendation

comments

EAU

- PSA >2ng/ml
- Symptomatic

- Bone scan 24, 25, 26, 27, 28, 29! - CT

(If negative repeat when PSA >5ng/ml and after PSAdt)

- mCRPC - monitoring of treatment

- CT-chest - CT-abdomen/pelvis - Bone scan

(Repeated every 6 months)

NCCN(Version: 2.2017)

Castration-naïve

- Bone scan - X ray-chest - CT/MRI-abdomen/pelvis with and without contrast Consider:- Choline PET30, 31!

Monitoring mCRPC

- CT/MRI - Bone scan

(Every 6-12 months) (Every 8-12 weeks)

APCCC 2017 (Delphi method >75% agreement)

Oligometastatic castration-naïve Pca

-NoCT-abdomen/pelvis or Bone scan

Staging and monitoring mCRPC when treating with Ra-223

- CT-Thorax/Abdomen - Bone scan

APCC 2015

mCRPC

- CT-chest - CT-abdomen/pelvis - Bone scan - No routine WB-MRI or PET/CT for staging

(Before start of treatment)

PCWG3

If locally persistent/recurrent

- Multiparametric MRI

All patients

- CT-chest(<5 mm slices) - CT-abdomen/pelvis (<5 mm slices) - Bone scan - WB-MRI and PET/CT (all tracers) not recommended

  1. Miyoshi Y, Yoneyama S, Kawahara T, et al. Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases. BMC Cancer 2016; : 1–7.
  2. Poulsen MH, Rasmussen J, Edenbrandt L, et al. Bone Scan Index predicts outcome in patients with metastatic hormone-sensitive prostate cancer. BJU Int 2016; 117: 748–53.
  3. Reza M, Bjartell A, Ohlsson M, et al. Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy. EJNMMI Res 2014; 4: 58.
  4. Armstrong AJ, Kaboteh R, Carducci MA, et al. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol 2014; 32:
    1308–16.
  5. Kaboteh R, Gjertsson P, Leek H, et al. Progression of bone metastases in patients with prostate cancer – automated detection of new lesions and calculation of bone scan index. EJNMMI Res 2013; 3: 64.
  6. Ulmert D, Kaboteh R, Fox JJ, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urol 2012; 62: 78–84.
  7. Ceci F, Castellucci P, Nanni C, Fanti S. PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2103–4.
  8. Schwarzenböck SM, Eiber M, Kundt G, et al. Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory
    prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2105–13.

Imaging characteristics and evidence level

Imaging modality 

Newly diagnosis staging

BCR

CRPC

ROC characteristics

Evidence level

ROC characteristics

Evidence level

ROC characteristics

Evidence level

SIM

CT

Node:

Sens +

Spec ++

2a/B

Limited value and not recommended unless a high PSA value

3b/B

NA

2a/B

Bone scintigraphy

Bone:

Sens +++

Spec +++

3a/B

Limited value and not recommended unless PSA >10 ng/mL 

3b/B

‘2+2 rule’ recommended by PCWG

3b/B

MIM

18F-NaF

Bone:

Sens ++++

Spec +++

PPV+++

NPV ++++

2a/B

NA

NA

NA

NA

18!F-Choline

Bone:

Sens +++

Spec ++++

Node: 

Sens ++

Spec ++++

PPV+++

NPV ++++

2a/B



1b/A

Patient basis

Sens +++

Spec +++

Influenced by PSA level at recurrence

2a/B

Bone & soft tissue:

Sens++++

Spec ++++

PPV++++

NPV ++++

2b/B

WB-MRI with DWI

Bone:

Sens++++

Spec++++

AUC ++++

2a/B

Positive at low PSA levels 

2b/B

Anatomic and functional criteria

2b/B

PSMA

Bone:

Sens +++

Spec ++++

Node: 

Sens++

Spec++++

PPV+++

NPV +++

2b/B

Patient basis:

Sens +++

Spec +++

Influenced by PSA level at recurrence

2a/B

Not reliable for AR axis targeting treatments

NA


“+” <50%;
“++” 50%-69%;
“+++” 70%-89%;
“++++” 90%

AR= androgen receptor;
BCR= biochemical relapse;
CRPC= castration-resistant prostate cancer;
DWI=diffusion weighted imaging;
NA=no adequate data in this population or similar ROC and evidence level to staging;
NPV=negative predictive value;
PPV=positive predictive value;
PCWG=prostate cancer working group;
PSA= prostate-specific antigen;
PSMA= prostate-specific membrane antigen;
ROC= receiver operating characteristic;
Sens= sensitivity;
Spec=specificity;
WB-MRI=whole body- magnetic resonance imaging

 

Become A Member Today!

You will have access to a wide range of benefits that can help you advance your career and stay up-to-date with the latest developments in the field of radiology. These benefits include access to educational resources, networking opportunities with other professionals in the field, opportunities to participate in research projects and clinical trials, and access to the latest technologies and techniques. 

Check out our different membership options.

If you don’t find a fitting membership send us an email here.

Membership

for radiologists, radiology residents, professionals of allied sciences (including radiographers/radiological technologists, nuclear medicine physicians, medical physicists, and data scientists) & professionals of allied sciences in training residing within the boundaries of Europe

  • Reduced registration fees for ECR 1
  • Reduced fees for the European School of Radiology (ESOR) 2
  • Exclusive option to participate in the European Diploma. 3
  • Free electronic access to the journal European Radiology 4
  • Content e-mails for all ESR journals
  • Updates on offers & events through our newsletters
  • Exclusive access to the ESR feed in Juisci

€ 11 /year

Yes! That is less than €1 per month.

Free membership

for radiologists, radiology residents or professionals of allied sciences engaged in practice, teaching or research residing outside Europe as well as individual qualified professionals with an interest in radiology and medical imaging who do not fulfil individual or all requirements for any other ESR membership category & former full members who have retired from all clinical practice
  • Reduced registration fees for ECR 1
  • Free electronic access to the journal European Radiology
  • Content e-mails for all 3 ESR journals 4
  • Updates on offers & events through our newsletters
  • Exclusive access to the ESR feed in Juisci

€ 0

The best things in life are free.

ESR Friends

For students, company representatives or hospital managers etc.

  • Content e-mails for all 3 ESR journals 4
  • Updates on offers & events through our newsletters

€ 0

Friendship doesn’t cost a thing.

The membership type best fitting for you will be selected automatically during the application process.

Footnotes:

01

Reduced registration fees for ECR 2024:
Provided that ESR 2023 membership is activated and approved by August 31, 2023.

Reduced registration fees for ECR 2025:
Provided that ESR 2024 membership is activated and approved by August 31, 2024.

02
Not all activities included
03
Examination based on the ESR European Training Curriculum (radiologists or radiology residents).
04
European Radiology, Insights into Imaging, European Radiology Experimental.